Lariam

(mefloquine)

ApprovedSmall molecule

Mefloquine is used to prevent and treat malaria, a serious disease spread by mosquitoes in tropical regions around the world.[2] Lariam is currently approved and in use across 7 indications[4].[1]

Lariam is one of 183 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

182

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionApproved

Plasmodium Falciparum MalariaApproved

MalariaActive, not recruiting

Urinary SchistosomiasisActive, not recruiting

COVID-19Approved

Progressive Multifocal LeukoencephalopathyActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

HIV InfectionApproved

Approved

Plasmodium Falciparum MalariaApproved

Approved

MalariaPhase 3

Active, not recruiting

Urinary SchistosomiasisPhase 2

Active, not recruiting

COVID-19Approved

Approved

Progressive Multifocal LeukoencephalopathyPhase 1

Active, not recruiting

Glioblastoma MultiformePhase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Lariam

UUnited BioPharma

Approved

21 2

Spikevax

Moderna

Preclinical

21 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Nexavar

Bayer

Preclinical

1 5

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Benadryl

PParkedale

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 9

Orap

Teva

Preclinical

1 10

Calcium

Eli Lilly

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria7 trials

The Effect of Malaria on Disease Progression of HIV/AIDS

Completed·LLondon School of Hygiene and Tropical Medicine·N/A·NCT00499876·197 enrolled

A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

Completed·OORIYOMI OMOTOYOSI AKINYOTU·Phase 1·NCT02524444·142 enrolled

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

Completed·UU.S. Army Medical Research and Development Command·N/A·NCT00761020·31 enrolled

Show 4 more trials

Antimalarial Drug Resistance in Mali

Completed·CCenters for Disease Control and Prevention·N/A·NCT00127998·1,011 enrolled

Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00082576·238 enrolled

Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02612545·216 enrolled

Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.

Completed· Pfizer logo

Pfizer·Phase 3·NCT00367653·397 enrolled

ART2 trials

Assessment of Artesunate/Mefloquine in the Peruvian Amazon

Completed·IInstituto Nacional de Salud. Peru·Phase 4·NCT02084602·45 enrolled

Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects

Completed·UUniversity of Oxford·Phase 4·NCT02324738·16 enrolled

Pregnancy2 trials

Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine

Completed·IInstitut de Recherche pour le Developpement·Phase 3·NCT00970879·430 enrolled

Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy

Completed·HHospital Clinic of Barcelona·N/A·NCT00811421·5,820 enrolled

Combination Therapy2 trials

Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand

Completed·—·N/A·NCT01659281·13 enrolled

In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy

Completed·GGlobal Emerging Infections Surveillance and Response System·Phase 4·NCT01976780·118 enrolled

Prophylaxis1 trial

Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial

Completed·IInstitute of Tropical Medicine, Belgium·N/A·NCT00373048·300 enrolled

7 more indications

Trial1 trial

Kilimanjaro IPTi Drug Options Trial

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 2/3·NCT00158574·2,419 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Terminated· Biogen logo

Biogen·Phase 1/2·NCT00746941·37 enrolled

Plasmodium Falciparum1 trial

A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT02488902·521 enrolled

Effectiveness1 trial

A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19

Completed·BBurnasyan Federal Medical Biophysical Center·Phase 2/3·NCT04347031·320 enrolled

Urinary Schistosomiasis1 trial

Activity of Mefloquine Against Urinary Schistosomiasis

Completed·—·Phase 2·NCT01132248·65 enrolled

Glioblastoma Multiforme1 trial

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01430351·144 enrolled

Unspecified1 trial

An Evaluation of Weekly Tafenoquine

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT02488980·306 enrolled

Regulatory

FDA Approval Timeline[5]

May 2, 1989

LARIAM

NDA NDA019591

May 2, 1989

MEFLOQUINE HYDROCHLORIDE

NDA NDA019578

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for mefloquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Lariam drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — mefloquine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for mefloquine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA019591). U.S. Food & Drug Administration.
[6]
SEC EDGAR — United BioPharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: UUnited BioPharma

Lariam

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Malaria7 trials

ART2 trials

Pregnancy2 trials

Combination Therapy2 trials

Prophylaxis1 trial

Trial1 trial

Progressive Multifocal Leukoencephalopathy1 trial

Plasmodium Falciparum1 trial

Effectiveness1 trial

Urinary Schistosomiasis1 trial

Glioblastoma Multiforme1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News